Bildkälla: Stockfoto

Egetis Therapeutics: Continued progress in Q4 - Redeye

Redeye updates its view of Egetis following the Q4 report and recent events in the company. The company has made some good progress and we see 2024 as a pivotal year for the company in its transformation to a soon commercial company.

Redeye updates its view of Egetis following the Q4 report and recent events in the company. The company has made some good progress and we see 2024 as a pivotal year for the company in its transformation to a soon commercial company.
Börsvärldens nyhetsbrev
ANNONSER